Summary of Xencor Fireside Chat Company Overview - **Company**: Xencor - **Industry**: Biotechnology, specifically focusing on oncology and autoimmune diseases Key Points and Arguments Expansion into Immunology - Xencor has expanded into immunology, focusing on delivering new medicines for oncology and autoimmune diseases using differentiated molecules designed with XmAb protein design tools [2][3] Oncology Pipeline Developments - The company is focusing its oncology portfolio on T-cell engagers, with significant progress in various programs: - XmAb 942, a long-acting TL1A antibody, has completed phase one and is now in a phase 2b study for ulcerative colitis [4] - XmAb 819, an ENPP3xCD3 T-cell engager for renal cell carcinoma, showed a 25% objective response rate in a heavily pretreated population [5] - Plans for phase three trials are expected next year, with pivotal studies anticipated in 2027 [6] Autoimmune Disease Focus - Xencor is advancing its autoimmune pipeline with promising candidates: - Plamotamab (CD20xCD3) is in phase one for rheumatoid arthritis (RA) [4] - The company aims to leverage its experience from oncology to develop effective dosing regimens for autoimmune diseases [27] Differentiation of XmAb 942 - XmAb 942 is designed to maximize drug exposure and potency, potentially making it best-in-class in the crowded anti-TL1A space [12][15] - The development plan emphasizes a single subcutaneous administration every 12 weeks, enhancing convenience for patients [15] Competitive Landscape in IBD - Xencor's products are positioned in a competitive market for inflammatory bowel disease (IBD), with a focus on differentiating their offerings from first-generation drugs [24] - The company anticipates a future with various biosimilar options, enhancing treatment flexibility [25] Clinical Execution and Milestones - The company emphasizes a strong focus on clinical execution, aiming to deliver timely updates and milestones to investors [7][8] - The phase 2b study for XmAb 942 is designed to efficiently identify a recommended phase three dose [16] Insights on Plamotamab and CD19/CD20 Programs - Xencor is applying learnings from oncology to develop Plamotamab for RA, focusing on ease of administration and deep B-cell depletion [27][28] - The company is exploring indications that address high unmet needs, particularly in RA, with a focus on safety and efficacy [32] Other Important Content - Xencor's strategy includes a rigorous approach to clinical trial design, aiming for efficient pathways to market [16][22] - The company is optimistic about the potential of bispecific therapies to enhance treatment outcomes in autoimmune diseases [19][20] - The leadership expressed excitement about the upcoming data and milestones, indicating a proactive approach to investor communication [17][18]

Xencor (XNCR) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +88.89%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.78 per share when it actually produced a loss of $0.41, delivering a surpr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ _______________________________________________ Commission file num ...

Exhibit 99.1 Xencor Reports Third Quarter 2025 Financial Results PASADENA, Calif.--Nov. 5, 2025-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025 and provided recent business and clinical program updates. "Xencor's two novel, first-in-class, CD3 T-cell engaging bispecific antibodies, XmAb819 and XmAb541, have demonstrated ...

Core Insights - Xencor is advancing its clinical trial programs with two first-in-class bispecific antibodies, XmAb819 and XmAb541, targeting specific cancer types, showing promising initial results [1][7] - The company reported significant revenue growth in Q2 2025, primarily from milestone payments and royalties, indicating a strong financial position despite not having marketed drugs [2] - Xencor has a diverse pipeline with over a dozen drug candidates at various development stages, showcasing its robust research capabilities [3][4] Group 1: Clinical Development - XmAb819 targets clear cell renal cell carcinoma (ccRCC) and has shown a 25% overall response rate in heavily pretreated patients during Phase 1 trials [1] - XmAb541 is under evaluation for advanced solid tumors expressing CLDN6, with ongoing Phase 1 dose escalation studies [7] - The company plans to recommend a Phase 3 dose for XmAb819 next year and initiate pivotal studies by 2027 [1] Group 2: Financial Performance - Xencor's Q2 2025 revenue reached $43.6 million, an 82% increase compared to Q2 2024, driven by milestone payments and non-cash royalties [2] - The company does not market any approved drugs directly but benefits from royalties on licensed products [2] Group 3: Analyst Sentiment - Despite a 39% decline in stock price year-to-date, analysts like Barclays's Etzer Darout have upgraded Xencor to Overweight, citing positive updates on its pipeline [8][9] - The consensus rating for Xencor stock is Strong Buy, with 12 Buy ratings and a price target suggesting an 85% potential gain over the next 12 months [11]

Core Points - The webcast is focused on the initial Phase I dose escalation results for Xencor's XmAb819 [1] Group 1 - The conference is hosted by Megan, the conference operator, who introduces the event [1] - Charles Liles, Senior Director of Corporate Communications and Investor Relations, is set to take over the call [1]

Summary of Xencor XmAb® 819 Initial Phase I Dose Escalation Results Webcast Company and Industry Overview - **Company**: Xencor - **Product**: XmAb® 819 - **Industry**: Oncology, specifically targeting advanced clear cell renal cell carcinoma (ccRCC) Core Points and Arguments 1. **Positive Initial Results**: Xencor announced positive initial results from the Phase I dose escalation study of XmAb® 819 in advanced ccRCC, indicating potential for significant anti-tumor activity in heavily pretreated patients [2][20][29] 2. **T-cell Engager Mechanism**: XmAb® 819 is a first-in-class XmAb® 2+1 T-cell engager targeting ENPP3, designed to selectively engage tumor cells while minimizing effects on normal cells [8][19] 3. **Patient Population**: The study enrolled patients with a median of four prior systemic therapies, with over 36% having prior HIF2 inhibitor therapy, highlighting the advanced nature of the patient population [13][31] 4. **Efficacy Data**: The best overall response rate observed was 25%, with a disease control rate of 70%, which is unprecedented for monotherapy in this heavily pretreated population [20][29] 5. **Safety Profile**: The drug was well tolerated, with a low rate of adverse events (AEs) and only 4% of patients discontinuing due to AEs. The most common AEs included cytokine release syndrome (CRS), rash, and gastrointestinal symptoms [14][18][50] 6. **Dosing Strategy**: The study utilized a priming step followed by a target dose regimen, with pharmacokinetic (PK) profiles supporting biweekly dosing after the first cycle [10][12] 7. **Market Potential**: The global drug sales for renal cell carcinoma are projected to reach $12 billion by 2030, indicating a significant market opportunity for XmAb® 819 [27] 8. **Future Development**: Xencor plans to explore additional development opportunities in other tumor types expressing ENPP3, such as papillary renal cell, colorectal, and lung cancer [31] Additional Important Content 1. **Forward-Looking Statements**: The management made forward-looking statements regarding future product offerings and market conditions, emphasizing the uncertainty and risks involved [3][4] 2. **Dose Preparation Issues**: Initial dose preparation errors led to elevated drug levels and increased rates of CRS, but corrective measures have been implemented to prevent future occurrences [16][52] 3. **Combination Therapy Potential**: There is optimism about the potential for XmAb® 819 to be used in combination therapies, particularly as the drug shows promise in managing AEs and maintaining patient quality of life [25][66] 4. **Clinical Trial Dynamics**: Enrollment has accelerated as the study progresses, with a waitlist for patients indicating strong interest in the trial [55][56] 5. **Next Steps**: Xencor aims to establish a recommended Phase III dose for XmAb® 819 by 2026 and will continue to evaluate the drug's performance in various cohorts [26][79] This summary encapsulates the key points from the conference call regarding XmAb® 819, its clinical trial results, market potential, and future development strategies.

XmAb819 Clinical Trial - Key Findings - The Phase 1 dose-escalation study of XmAb819 in ccRCC showed a manageable safety profile, with most CRS events being Grade 1/2 and occurring during priming [47, 51, 136] - Correct dose preparation resulted in 4% Grade 3 CRS (2/51), while dose preparation errors led to 28% Grade 3 CRS (5/18) [40, 136] - In the target dose range, correct dose preparation resulted in 6% Grade 3 CRS (1/18), while dose preparation errors led to 50% Grade 3 CRS (3/6) [40, 136] - XmAb819 demonstrated an objective response rate (ORR) of 25% (95% CI: 9-49) and a disease control rate (DCR) of 70% (95% CI: 46-88) in the efficacy-evaluable target dose range (N=20) [55, 89, 125] - The median number of prior regimens for patients in the XmAb819 study was 4 (range: 1-8), with 70% having received ≥3 prior regimens [35, 89, 119] XmAb819 Development & Market Opportunity - Xencor is planning to start a pivotal study of XmAb819 as monotherapy in advanced ccRCC in 2027 [79, 104] - The global RCC market is expected to reach approximately $12 billion by 2030 [80] - In the U S, there are approximately 60,000 new cases of ccRCC per year [84] XmAb541 Early Results - Early data from the Phase 1 dose escalation study of XmAb541 showed promising anti-tumor activity in advanced ovarian cancer, endometrial cancer, and germ cell tumors [4, 93, 97] - The total sales in 1H25 for ovarian cancer drugs were $338 million, and for endometrial cancer drugs were $196 million [100]

Core Insights - Xencor, Inc. announced initial results from a Phase 1 dose-escalation study of XmAb819, a bispecific antibody targeting ENPP3 and CD3, for treating advanced clear cell renal cell carcinoma (ccRCC) [1] Company Overview - Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune diseases [1] Study Details - The results of the ongoing Phase 1 study were presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics [1]

Core Insights - Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune diseases [1] - The company will host a conference call and webcast on October 24 to discuss initial results from a Phase 1 dose-escalation study of XmAb819 [1] - XmAb819 is a bispecific antibody targeting ENPP3 and CD3, specifically developed for patients with advanced clear cell renal cell carcinoma [1] Company Overview - Xencor, Inc. is listed on NASDAQ under the ticker XNCR [1] - The company specializes in engineered antibodies, indicating a focus on innovative therapeutic approaches in the biopharmaceutical sector [1] Upcoming Events - The conference call and webcast are scheduled for October 24 at 1:30 p.m. ET (10:30 a.m. PT) [1] - This event will provide insights into the ongoing clinical study and its implications for the treatment of advanced clear cell renal cell carcinoma [1]